SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
Conditions: HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Interventions: Drug: SHR-A1811; Drug: Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan Sponsors: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Conditions: Breast Neoplasms Interventions: Procedure: Sentinel Lymph Node Biopsy (SLNB); Drug: Doxorubicin; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Cyclophosphamide; Drug: Fludarabine; Biological: Tumor-draining lymph node-derived lymphocyte (LNL); Biological: Interleukin-2; Drug: Nab-paclitaxel Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Conditions: Breast Neoplasms Interventions: Procedure: Surgery for harvesting tumor-draining lymph nodes; Drug: Cyclophosphamide; Drug: Fludarabine; Biological: Tumor-draining lymph node-derived lymphocyte (LNL); Biological: Interleukin-2; Biological: Camrelizumab; Drug: Chemotherapeutic drug, ADC or PARP inhibitor Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Conditions: Advanced Solid Tumor; Advanced Breast Cancer; Metastatic Breast Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Hormone Receptor Positive Malignant Neoplasm of Breast; HER2-negative Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Non-small Cell Lung Cancer Interventions: Drug: BGB-43395; Drug: Fulvestrant; Drug: Letrozole Sponsors: BeiGene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer
Conditions: Non-small Cell Lung Cancer Interventions: Drug: BL-M07D1 Sponsors: Sichuan Baili Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Dato-DXd; Drug: Durvalumab; Drug: Pembrolizumab; Drug: Doxorubicin; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Paclitaxel; Drug: Carboplatin; Drug: Capecitabine; Drug: Olaparib Sponsors: AstraZeneca; Daiichi Sankyo, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials
Mobile Health for Adherence in Breast Cancer Patients
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Breast Carcinoma; HER2-Negative Breast Carcinoma; Hormone Receptor-Positive Breast Carcinoma Interventions: Other: Electronic Health Record Review; Other: Health Promotion and Education; Procedure: Health Telemonitoring; Other: Interview; Behavioral: Patient Navigation; Other: Survey Administration; Other: Text Message-Based Navigation Intervention Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
Conditions: GastroEsophageal Cancer; Gastric Cancer Interventions: Drug: Neratinib; Drug: Trastuzumab; Drug: Oxaliplatin; Drug: 5-Fluorouracil + leucovorin; Drug: Pembrolizumab Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Puma Biotechnology, Inc.; National Comprehensive Cancer Network Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2023 Category: Research Source Type: clinical trials
Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer
Conditions: Breast Cancer Interventions: Behavioral: Intermittent Fasting Sponsors: Medical College of Wisconsin Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab ® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer
Conditions: HER2-positive Breast Cancer Interventions: Drug: HS022; Drug: Trastuzumab; Drug: Vinorelbine Bitartrate Sponsors: Zhejiang Hisun Pharmaceutical Co. Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Conditions: Advanced or Metastatic Breast Cancer Interventions: Drug: PF-07220060; Drug: Fulvestrant; Drug: Everolimus; Drug: Exemestane Sponsors: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials
Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer
Conditions: Breast Neoplasms Interventions: Drug: Disitamab Vedotin; Drug: Toripalimab Sponsors: RemeGen Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
Conditions: HER2-negative Breast Cancer; Advanced Breast Cancer Interventions: Drug: Organoid-guided treatment; Drug: Taxane; Drug: Capecitabine; Drug: Gemcitabine; Drug: Vinorelbine; Drug: Eribulin Sponsors: Guangdong Provincial People ' s Hospital; First Affiliated Hospital, Sun Yat-Sen University; Sun Yat-sen University; Shantou Central Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2023 Category: Research Source Type: clinical trials
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After progrEssion on ENhertu (SATEEN)
Conditions: Her 2 Positive Breast Cancer; Breast Cancer Female; Breast Cancer Metastatic Interventions: Drug: Sacituzumab Govitecan; Drug: Trastuzumab; Drug: Trastuzumab and Hyaluronidase-oysk Sponsors: Adrienne G. Waks; Gilead Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With HER2+ Locally Advanced and/ or Metastatic Solid Tumors
Conditions: Solid Tumor Interventions: Biological: Intravenous infusion anti-HER2-CAR-T cell Sponsors: China Medical University, China; Shanghai First Song Therapeutics Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials
